Roche to expand Rocephin production facility in Kaiseraugst
Investment of about 35 million Swiss francs

Roche announced today that the local authorities in Kaiseraugst have approved the company’s application for planning permission to expand production facilities for the antibiotic Rocephin. Because of the age of the existing plant, Roche is investing in a new, high-tech filling line to help meet continued global demand for Rocephin. The new line will replace two existing ones at the site. Expenditure for this latest plant expansion in Kaiseraugst is expected to total about 35 million Swiss francs.

“This investment once again underscores the strategic importance of the Kaiseraugst site for Roche,” said Matthias M. Baltisberger, Roche Basel Site Head. “The planned expansion of the Rocephin filling plant shows our commitment to manufacturing important drugs like Rocephin even after they go off patent and making a significant contribution to the supply of antibiotics to patients.”

Work is due to begin in autumn 2012, with the new facility scheduled to be operational in late 2014.

Rocephin has been produced and packaged in Kaiseraugst since 1986 and is shipped from the site to 160 countries worldwide. Over 100 million people around the world have been successfully treated with the antibiotic.

About Roche in Kaiseraugst
Roche Kaiseraugst has been the home of one of Europe’s most modern pharmaceutical packaging and logistics centres since 1995. Production and logistics facilities at the site today supply medicines to over 130 countries. The plant is being expanded in response to growing global demand for Roche biopharmaceuticals such as Actemra, Avastin, Herceptin, MabThera and Pegasys, which have to be stored, packed and shipped under refrigerated conditions. This will enable Roche to take full advantage of synergies with the existing infrastructure while guaranteeing an integrated supply chain. Kaiseraugst plays a central role within the Roche Group. Roche acquired the Kaiseraugst site in the early 1970s. In recent years the Group has invested
some 400 million Swiss francs in the construction of a sterile manufacturing facility, a new quality control and quality assurance laboratory building and a new logistics centre (currently under construction) at the site.

**About Roche**

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: [www.roche.com](http://www.roche.com).

All trademarks used or mentioned are protected by law.

**Roche Group Media Office**

Phone: +41 -61 688 8888 / e-mail: basel.mediaoffice@roche.com

- Alexander Klauser (Head)
- Silvia Dobry
- Daniel Grotzky